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Cell surface glycoproteins encoded by the I region of the murine major histocom- 
patibility  complex  play  a  central  role  in  regulating  lymphoid  cell  interactions. 
Macrophage-T cell (1, 2)  and T  cell-B cell (3, 4)  collaborations are dependent  upon 
homology at  this  region,  in  most  cases  mapping to  the  I-A subregion  of the  H-2 
complex.  Because  it  has  not  been  possible to  separate by recombination  I  region- 
associated  (Ia)  antigen  expression  and  immune  response  (Ir)  gene  phenotypes  of 
inbred  mouse  strains,  it  appears  that  Ia  antigens  may  be  the  vehicles  of Ir  gene 
function  (5).  This is supported by biochemical and functional studies on the genetic 
control of Ia antigen synthesis (6,  7). T  cells (8), B cells (9,  10), and macrophages (11, 
12)  have  all  been  implicated  as  possible sites  of Ir  gene  expression,  although  the 
precise mechanism(s) of gene action are still a matter of conjecture (13). 
Immune  responsiveness  to  antigens  under  Ir  gene  control  has  been  modulated 
experimentally through the use of antibodies specific for the cell surface products of 
these loci. Inhibition of antigen-specific T  cell proliferation in vitro has been accom- 
plished using monoclonal anti-Ia antibodies specific for the controlling Ia subregion 
(14), or, in the case of antigens under complementing Ir gene control, with antibodies 
raised against the hybrid Ia determinant  (5).  Such antibodies act at the level of the 
macrophage under these conditions (15)  and function, at a minimum, by blocking T 
cell  binding  to  I-A  +  antigen-presenting  cells  (16).  The  observable  effect  of these 
manipulations is the abrogation of T  cell stimulation  because of ineffective macro- 
phage-T cell interaction. 
I  subregion-specific antibodies have also been shown to exert profound effects on 
antigen-specific reactivity when administered in vivo, where results are again consist- 
ent with antibody-mediated interference with macrophage-dependent T  cell antigen 
recognition.  Previous  work  from  this  laboratory  has  revealed  that  Lyt-1  ÷  T  cell 
responses to syngeneic tumor antigen, assayed either by tumor rejection (17) or by the 
expression of delayed type-hypersensitivity (DTH) 1 (18), are inhibited  by the intra- 
venous injection of anti-I-A alloantisera.  Inhibition of DTH in a  hapten model was 
shown  to be specific for the I-A genotype of the hapten-coupled antigen-presenting 
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cell  (18),  and  resulted  in a  loss of transferrable  DTH  reactivity.  Other laboratories 
have reported similar effects of in vivo monoclonal anti-I-A antibody treatment on T 
helper  cell  activity  (19),  Ir  gene-controlled  antibody  production  (20),  and,  most 
recently,  on  the  induction  of murine  experimental  allergic  encephalitis  (21).  The 
capacity of antibodies directed against products of the Ir gene loci to alter the course 
of cell-mediated immunity in vivo in each of these widely divergent systems supports 
the  hypothesis  that  this  means  of therapy  may  be  effective  in  regulating  T  cell 
responses to any antigen  that undergoes macrophage processing before T  cell recog- 
nition  (18). 
Because of the complexity of cell interactions  that serve to maintain  order within 
the immune system, it would appear almost inevitable that perturbation of any single 
aspect of a  multicellular response may have repercussions at some other level. In this 
report, we demonstrate this to be true in animals treated with I-A subregion-specific 
antibodies.  As briefly described  elsewhere  (22),  the administration  of anti-I-A anti- 
bodies to mice immunized  for tumor-specific DTH  reactivity  is associated  with  the 
development  of antigen-specific  suppressor  T  cell  (Ts)  activity.  It  is  proposed  that 
activation of the suppressor cell circuit provides a  mechanism to maintain  Lyt-1 + T 
cell  nonresponsiveness  in  the  absence  of continued  antibody  treatment  (18),  thus 
amplifying the primary effect of anti-I-A antibodies  on macrophage presentation  of 
antigen. 
Materials  and Methods 
Mice.  8-10-wk-old female A/J (H-2  a) mice, obtained from The Jackson Laboratory, Bar 
Harbor, ME, were used in all experiments. 
Immunization.  The  maintenance  and  growth characteristics  of the  S1509a  and  SA1  A/J 
methylcholanthrene (MCA)-induced fibrosareomas havee been described previously (23). Ani- 
mals were immunized by subcutaneous injection of 10  ascites-derived S 1509a cells given 7,800 
rad of irradiation in a Gammacell 40 (Atomic Energy of Canada, Ottawa, Canada)  (18). DTH 
responses  were elicited by footpad challenge 5 d later with 106 similarly irradiated cells in a 30- 
#1 vol (18). Differences in swelling between injected and uninjected footpads were measured 
after 24 h and compared with swelling responses of unimmunized control mice. This immuni- 
zation protocol has been shown to induce transferable, antigen-specific Lyt-1  + T cell-mediated 
DTH reactivity (24), but differs from a live tumor cell challenge in that the suppressor circuit 
is not activated (23, 24). 
Adoptive  Transfers.  Adoptive transfers were performed  as described  previously  (18) using 
single cell  suspensions of spleen,  thymus, or lymph nodes obtained 5 d  after immunization. 
5 X 107 ceils were injected intravenously into normal recipients immunized simultaneously with 
irradiated S1509a cells subcutaneously as above. 
Cyclophosphamide  Treatment.  Elimination  of suppressor  cell  precursors  was  attempted  by 
intraperitoneal injection of 20 mg/kg Cytoxan (Mead Johnson & Co., Evansville, IN) in saline 
3  d  before  immunization  (25).  This  protocol has  been effective in  reducing suppressor cell 
activity in mice bearing progressive MCA-induced tumors, resulting in the loss of transferrable 
suppression (25). 
Anti-LA Antibodies.  Antibodies used in most experiments consisted ofa (B10 ×  LP.RIII)FI 
anti-B10.A(4R)  antiserum specific for K  and I-A antigens of the H-2  a haplotype. Characteri- 
zation of this  antiserum  and  the singular role of anti-I-A antibodies  in inhibition  of T  cell 
responses have been reported previously (17). In the present experiments, animals received daily 
intravenous injections of 2-5/~1 antiserum in a 0.2 ml. volume of Hanks' balanced salt solution 
(HBSS). Monoclonal anti-I-A  k antibodies used in certain experiments consisted of protein A- 
Sepharose-purified culture supernatants of the 10-2.16 or 10-3.6 hybridomas (both recognizing 
public specificity Ia. 17). The latter antibodies were kindly donated by Dr. R. Germain, Harvard 
Medical School, Boston, MA. 20 #g of these antibody preparations were administered intrave- 482  ANTI-I-A ANTIBODY-INDUCED  SUPPRESSOR  T  CELLS 
nously per mouse per day in 0.2 ml  HBSS. Monoclonal anti-I-A  d antibody used  in certain 
specificity experiments was derived from culture supernatants of the MKD6 hybridoma cell 
line,  generously donated by Dr. J. Bersofsky, National Cancer Institute, Bethesda, Md. 
Antibody and Complement (C')  Treatment.  The  murine  hybridoma line,  HO-13.4,  obtained 
from the Salk Institute, La Joila, CA, was used as a source of monoelonal anti-Thy-1.2 antibody. 
Aliquots of 2  ×  10  s spleen cells  were resuspended  in 4  ml  HO-13.4 culture supernate  and 
incubated on ice for 30 min. After washing in HBSS, 2 ml of a  1:12 dilution of low toxicity 
rabbit C' (Cedarlane Laboratories, Ltd., Hornby, Ontario, Canada) was added, and cells were 
incubated for an additional 30 min at 37°C. Cells were then washed twice more and subjected 
to a second treatment by incubation in 1 ml HO-13.4 supernate plus  1 ml of a  1:6 dilution of 
C' for 15 min at 4°C followed by 5 min at 37°C. Cells remaining after this double treatment 
were resuspended  at  2.5  ×  108 viable cells/ml  in  HBSS and  0.2  ml of this suspension  was 
injected intravenously into recipient mice. 
Statistical Significance.  The mean difference between groups of five mice were analyzed on 
the Wang programmable computer (Wang Laboratories, Inc., Lowell, MA) using the Student's 
t test. 
Results 
Generation of Antigen-specific Suppressor Cells as a Consequence of  Anti-I-A Antibody Treatment 
In Vivo.  The expression of Lyt-1 + T  cell responses to syngeneic MCA-induced tumor 
antigen  can  be  inhibited  by  the  in  vivo  administration  of I-A subregion-specific 
antisera  (17,  18),  presumably  as  a  result  of interference  with  macrophage-T  cell 
interactions during antigen presentation in vivo (18). Because previous studies revealed 
that the administration  of only 4 #1 of an anti-K  k, I-A  k antiserum  over a  2-d period 
was sufficient to inhibit DTH responsiveness 5 d  later (18), it was reasoned that some 
additional  mechanism  may be  functioning to  amplify the  in  vivo activity  of these 
antibodies.  As  one  approach  to  this  issue,  experiments  were  designed  to  assay  for 
suppressor cell function in anti-I-A antibody-treated mice (22). 
The question of Ts activation by anti-I-A antibody administration  was addressed 
by analyzing the DTH  response to syngeneic tumor antigen,  because immunization 
for DTH can be achieved using irradiated  tumor cells and is not complicated by the 
spontaneous  activation  of suppressor  cells  that  occurs  after  a  live  tumor challenge 
(23). A/J (H-2  a) mice were inoculated subcutaneously with 106 irradiated S 1509a cells 
and  treated  daily  with  5  /xl  (B10  ×  LP.RIII)F1  anti-B10.A(4R),  anti-K  k,  I-A  u 
aUoantiserum.  The in vivo activity of this antiserum has been attributed solely to the 
contribution of anti-I-A  k alloantibodies  (17). After 5 d, spleen cells from these or from 
untreated control mice were adoptive]y transferred  to normal A/J recipients.  Recip- 
ients  were  immunized  subcutaneously  within  the  hour  with  an  identical  dose  of 
S1509a  cells  and  DTH  responses  elicited  5  d  later  by  footpad  challenge  with  the 
immunizing tumor cell.  Results of one such experiment are shown in Fig.  1. Animals 
receiving  no  spleen  cells,  or cells  from  normal  or  immune  (but  untreated)  donors 
expressed comparable levels of DTH  reactivity. In contrast, animals receiving spleen 
cells from S 1509a-immune, anti-I-A  k antibody-treated donors exhibited a significantly 
depressed  DTH  response,  indicating  the  transfer of cells capable of suppressing  the 
induction of recipient  Lyt-1 + T  cell responses. 
The specificity of suppression is demonstrated in Table I. In this experiment, spleen 
cells from S 1509a-immunized anti-I-A  k antibody-treated mice were adoptively trans- 
ferred to recipients immunized with S 1509a or with SA 1, a second A/J MCA-induced 
fibrosarcoma that cross-reacts with S1509a at the effector level but induces a distinct 
suppressor  cell  (26).  As indicated,  suppressor  cells  induced  in  animals  primed  with LINDA L.  PERRY  AND MARK I.  GREENE 
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Fro.  1.  Induction of suppression  by in vivo anti-I-A antibody treatment. A/J mice were immunized 
by subcutaneous injection of l0  s 8,000-rad-irradiated  S1509a cells and treated daily for 5 d with 5 
#1 (B10 ×  LP.RIII)Fx anti-B10.A(4R), anti-K  k, I-A  k alloantiserum. Spleen cells from these or from 
normal or immunized (but untreated)  mice were removed on day 6 and adoptively transferred to 
syngeneic  recipients immunized subcutaneously with an identical dose of irradiated S1509a  cells. 
DTH responses  were evoked in recipient mice 5 d  later by footpad challenge with  106 irradiated 
S 1509a cells, and footpad swelling was measured 24 h after challenge. 
TABLE  I 
Specificity of Anti-I-A Antibody-induced Suppressor T Cells 
483 
Donor immu-  Antibody treat-  Spleen cells  Recipient im-  Recipient  Units of footpad 
nization  ment*  transferred  munization:~  challenge:~  swelling 
mm×  10 -2 + SEM 
--  --  --  $1509a  S1509a  27.4 +  2.6 
$1509a  Anti-I-A  k  5 ×  107  Sl509a  S1509a  13.5 +  1.4§ 
....  S1509a  11.4 ±  1.2§ 
--  --  --  SAI  SA1  23.1 +  2.1 
S1509a  Anti-I-A  k  5 ×  107  SA1  SAI  20.6 ±  1.8 
....  SAl  11.2 ±  1.0§ 
* Animals received intravenous  injections  of 2 p.l/d  (B10 X  LP.RIII)F]  anti-B10.A(4R),  anti-K  k,  I-A  k 
antiserum daily for 5 d. 
:~ Immunization was accomplished by subcutaneous  injection of 106 8,000-rad-irradiated  S1509a  or SAl 
cells in a  100-#l vol. Footpad challenge was performed by the same number of irradiated tumor cells but 
in a 30-#1 vol. Footpad swelling was measured 24 h later. 
§ Statistically significant,  P <  0.01. 
S 1509a cells specifically inhibited  responses  to S1509a  and  not  to related  SA1  tumor 
antigens.  The  specificity  of these  cells  for  antigens  unique  to  the  S1509a  tumor  is 
similar to that  of Ts arising during  progressive tumor  growth  in  vivo (26),  although 
their  activation  under  these conditions  is dependent  upon  antibody-mediated  inter- 
ference with the normal sequence of cellular events rather than a spontaneous response 
to replicating tumor  cells. 
Distribution and Cyclophosphamide Sensitivity of Anti-I-A  Antibody-induced  Ts.  Studies in 
a  number  of laboratories  have shown  that  Ts cells reside primarily in the spleen and 
thymus  (27-29),  and  that  Ts activity in  these organs  can be ablated by the injection 
of low  doses  of cyclophosphamide  (CY)  before  antigen  sensitization  (25,  30).  The 
distribution  and  CY  sensitivity  of  suppressor  cells  induced  by  anti-I-A  antibody 
treatment  were investigated to determine the extent of similarity between Ts active in 
these  widely  divergent  systems.  The  suppressive  capacity  of  spleen,  thymus,  and 484  ANTI-I-A ANTIBODY-INDUCED  SUPPRESSOR  T  CELLS 
lymph node cells from anti-I-A antibody-treated mice is demonstrated  in Fig. 2. It is 
apparent that suppression, shown to be T  cell-dependent by its sensitivity to treatment 
with monoclonal anti-Thy-1.2 and C', can be adoptively transferred with splenocytes 
or thymocytes but not with lymph node cells. A similar distribution has been identified 
for Ts induced during tumor progression in this system, although lymph nodes also 
appeared  to contain  a  small  proportion of the relevant  cells  (29).  The generation of 
Ts by a  2-d regimen of antibody treatment  is also depicted in Fig. 2, indicating that 
the cellular events relevant to Ts activation occur during the first 2 d of sensitization, 
corresponding to the expected period of macrophage presentation of tumor antigen to 
Lyt-1 + T  effector cells  (Te).  These  results  suggest  that  the  induction  of Ts activity 
may be a  primary means of maintaining inhibition of Te responses in the absence of 
further antibody treatment. 
Based upon these findings, it became of interest  to determine the extent to which 
suppressor cell function contributed to the in vivo activity of anti-I-A antibodies.  To 
accomplish this, we attempted  to ablate Ts precursors by intraperitoneal  injection of 
20 mg/kg CY 3 d  before immunization,  a  protocol that has been shown effective in 
diminishing Ts activity in mice given a  live tumor challenge  (25).  Results  presented 
in Table II demonstrate the effect of CY pretreatment  on the expression of DTH  in 
anti-I-A antibody-treated  mice.  Animals  treated  with  anti-I-A antiserum  alone  ex- 
hibited suppressed DTH reactivity, as expected, whereas injection of CY alone caused 
a  slight  enhancement  of T  cell  responses.  The  combination  of antibody  plus  CY 
treatment,  however, reversed the suppression normally obtained by antibody admin- 
istration,  indicating that the full effects of antibody treatment  may be observed only 
in the presence of an intact  suppressor cell system.  Interference with macrophage-T 
cell  communication  alone  by  the  small  concentration  of antibody  used  in  these 
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FIG.  2.  Distribution of anti-I-A antibody-induced Ts. A/J mice, immunized on day 0 with  l0 6 
8,000-rad-irradiated S 1509a cells, were treated with 5 #1/d (B 10 x LP.RIII)FI anti-B 10.A(4R) anti- 
K  k, I-A  k antiserum on the days indicated. Cells were removed on day 6 and adoptively transferred 
without further treatment  or after treatment  with normal mouse serum or anti-Thy-l.2  plus C'. 
Recipients were immunized simultaneously by subcutaneous injection of 10  6 irradiated S 1509a cells 
and challenged with an  identical dose of cells in the footpad 5 d later. Swelling responses were 
measured 24 h after challenge. LINDA L.  PERRY  AND MARK I.  GREENE 
TASLE II 
CY Sensitivity of Anti-l-A Antibody-induced Ts 
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Immuniza-  Antibody  Units of footpad 
CY pretreatment  tion*  treatment:[:  Challenge  swelling 
mm×  10 -2 4- SEM 
--  S1509a  --  S1509a  26.5 4- 3.4 
--  S1509a  Anti-I-A  k  S1509a  14.8 ± 2.2§ 
20 mg/kg  S1509a  --  S1509a  28.0 ± 3.2 
20 mg/kg  S1509a  Anti-I-A  k  S1509a  24.5 ± 3.4 
....  8.5 ± 2.3§ 
* See footnote to Table I. 
:1: See footnote to Table I. 
§ Statistically significant, P < 0.02. 
TABLE  III 
Inhibition of Tumor-specific DTH with Monoclonal Anti-I-A 
Antibody In Vivo 
Anti-I-A anti- 
Immunization  body  Challenge  Units of footpad 
treatment*  swelling 
mm  ×  10 -2 +  SEM 
S1509a  --  S1509a  22.6 + 0.9 
S1509a  serum  S1509a  10.2 4- 1.3~ 
S1509a  10-2.16  S1509a  14.2 ±  1.5:~ 
$1509a  10-3.6  S1509a  13.3 ± 2.1:~ 
--  --  S1509a  8.9 ±  1.2:~ 
* Animals received 2 #l/d (B10 ×  LP.RIII)Fx anti-Bl0.A(4R), anti-K  k, I-A  k 
alloantiserum or 20 /~g/d purified  10-2.16 or  10-3.6 hybridoma anti-I-A  k 
antibody for 5 d. 
Statistically significant, P < 0.005. 
experiments  appears  to  be  insufficient to  significantly dampen  the  expression  of 
Lyt- 1  ÷ T  cell-mediated immunity. 
Inhibition  of DTH  with  Monoclonal  Anti-I-A  Antibodies.  Because  of  the  potential 
specificity problems associated with the use of a  polyvalent alloantiserum, attempts 
were  made  to  reproduce  the  inhibitory effects  of anti-I-A  k  alloantibodies by  the 
administration of monoclonal anti-I-A  k antibody reagents. A/J mice were immunized 
by the usual protocol by subcutaneous injection of l0  s  irradiated S1509a cells and 
injected intravenously with 2 #l/d (B 10 ×  LP.RIII)F1 anti-B 10.A(4R), anti-K  k, I-A  k 
alloantibodies or with 20/zg/d of protein A-Sepharose-purified anti-I-A  k hybridoma 
culture fluid. Hybridomas used in these experiments consisted of the 10-2.16 and 10- 
3.6  cell  lines  that  secrete  monoclonal antibodies  recognizing an  I-A  determinant 
corresponding  with  public  specificity  Ia.17  (31).  As  indicated  in  Table  III,  the 
administration of either of these monoclonal antibody reagents inhibited the DTH 
response elicited upon footpad challenge with  l0  s irradiated S1509a cells. Inhibition 
was dose-dependent (data not shown) and was achieved only by the administration 
of antibodies recognizing the  relevant I-A determinants, as  treatment with similar 
quantities of a  monoclonal anti-I-A  a  reagent had  no effect  on DTH  responsiveness 
(data not shown). These results suggest that the cellular events involved in Lyt-1 + T 486  ANTI-I-A ANTIBODY-INDUCED SUPPRESSOR  T  CELLS 
cell activation in vivo can be dramatically altered by blocking single determinants on 
the antigen-presenting cell surface. 
Discussion 
Manipulation  of the cellular immune  response by the  in  vivo administration  of 
anti-I-A antibodies has now been accomplished in several experimental systems (17- 
21,  32).  Results  in  each  of these  studies  can  be  interpreted to reflect an  effect of 
antibody on the induction of Lyt-1  ÷ T  cell immunity, observed as decreased DTH 
(18), helper activity (19, 20), or autoimmune (21) responsiveness. We now report that 
one of the ultimate effects of anti-I-A antibody administration in vivo is the induction 
of antigen-specific Ts activity. 
We have been involved in an analysis of the effects of in vivo anti-I-A antibody 
treatment  on  the  DTH  and  tumor  rejection response of A/J  mice  to  a  syngeneic 
M(3A-induced fibrosarcoma, S 1509a (17,  18). Each of these responses is mediated by 
I-A(-) T  cells expressing the Lyt-1  + phenotype (22, 24), and can be inhibited by the 
intravenous administration  of an  anti-I-A  k alloantiserum  (17,  18).  Several lines of 
evidence suggested  a  primary effect of antibody on the initiation of Lyt-1  + T  cell 
responses by interference with  I-A-restricted antigen  presentation, although  it  was 
difficult to reconcile how such minute quantities of antibody could exert these potent 
biological effects, particularly in view of the absorptive capacity of Ia  ÷ B cells present 
in the circulation during intravenous antibody administration.  The present studies 
provide one viable explanation for this dilemma, because it appears that maintenance 
of the depressed state of immunity is mediated by Ts. 
Suppression was evidenced by the capacity of spleen or thymus cells from antibody- 
treated mice to abrogate the induction of recipient DTH responses to tumor antigen. 
(3ells  capable  of transferring  this  suppression  were  shown  to  be  T  cells  by  their 
sensitivity to monoclonal anti-Thy-l.2 plus (3'.  Specificity of Ts for S1509a tumor 
antigen(s) was demonstrated by the failure of these cells to alter responses of recipients 
immunized with SA1 tumor cells, a second MCA-induced fibrosarcoma (26). In these 
respects, i.e., distribution, action during the induction phase of the DTH response, 
and antigen specificity, the anti-I-A antibody-induced Ts closely resembles Ts acti- 
vated spontaneously during the course of progressive tumor growth (26, 29). The mere 
presence of tumor antigen as it is expressed on the surface of irradiated S 1509a cells 
is  an  insufficient stimulus  for Ts generation,  however, as shown  by the transfer of 
spleen cells from immunized but untreated donors. Suppressor cell induction under 
these  conditions is  dependent  instead  upon  an  undetermined sequence of cellular 
events initiated by the administration of I-A subregion-specific antibodies. 
The absolute requirement for suppressor cell function in this system was shown by 
demonstrating  that  pretreatment  with  (3Y  to  eliminate  Ts  precursors  (25)  also 
abrogated the inhibitory effects of in vivo antibody administration.  These findings 
suggest that the anti-I-A antibody-induced Ts is (a) CY sensitive, and (b) a necessary 
participant  in  the  cascade  of events  that  occurs  after  antibody  administration. 
Although  suppressor activity has not  yet been  reported in other in  vivo models of 
anti-I-A antibody effects (19-21, 32), several examples exist demonstrating supression 
after in vitro anti-I-A antibody treatments (33-35). Most notably, Broder et al.  (33) 
have identified in cultures of mitogen-stimulated human lymphocytes upon addition 
of an antiserum to human Ia-like antigens  (p 23, 30). More recently, Bersofsky and LINDA L. PERRY AND MARK I. GREENE  487 
Richman  (35)  have described transferrable suppression with washed, anti-I-A anti- 
body-treated macrophages, although it was not determined whether the macrophage 
suppressed secondary cultures directly or by inducing a Ts subset. It will be of great 
interest to compare the results we have obtained with the in vivo models of Sprent 
(19),  Rosenbaum  et  al.  (20),  and  Steinman  et  al.  (21), where  inhibition  has  been 
observed by similar antibody treatments. 
Several mechanisms can be envisioned to account for the generation of suppressor 
T  cells  in  the  presence  of antibodies  that  block macrophage  I-A  molecules.  It  is 
considered  unlikely  that  suppression  is  the  result  of a  direct  interaction  between 
antibody molecules and receptors on the Ts cell surface, because Ts reactive against 
tumor (36)  or numerous other (13)  antigens have been shown to express I-J- or I-C- 
encoded determinants, but consistently lack I-A-encoded cell surface structures. Thus, 
there  is  no  evidence  for  a  target  of anti-I-A  antibody  on  a  T  cell  that  effects 
suppression.  Experiments  performed  in  vitro  have  demonstrated  the  induction  of 
suppressor cells by high  concentrations of soluble  antigen  (37)  or by depletion  of 
macrophages and other adherent cells  (38). There is no a  priori  reason to assume a 
direct effect of anti-I-A antibody treatment on antigen levels because ingestion and 
catabolism of antigen by macrophages proceeds uninhibited under these conditions 
(39). The presence of such antibodies may alter antigen clearance indirectly, however, 
by limiting T  cell recruitment of mononuclear cells involved in  antigen  handling, 
thereby creating a  condition of antigen excess. Alternatively, I-A-specific antibodies 
may induce suppression by local effects on the redistribution of proteins within the 
macrophage plasma membrane. Although little information is available concerning 
the membrane organizational events underlying I-A-restricted T  cell antigen recog- 
nition, there is evidence that I region gene products function at the antigen-presenting 
cell surface  (11)  at  some point  after antigen  ingestion  and  catabolism  (39).  If I-A 
molecules serve as receptors for fragments of internally processed antigen  (39), the 
addition of antibodies capable of blocking membrane antigen-I-A interactions may 
allow  the  expression of processed antigen  in  an  uncomplexed  form or perhaps  in 
association with macrophage I-J determinants (40). Antigen presented in this context 
may then provide an activation signal for a suppressor cell precursor. Indeed, evidence 
has been presented for a role of macrophages in suppressor cell interactions (41, 42), 
although  the  point  at  which  antigen  presentation  may be  required  has  not  been 
determined.  Further  functional  and  phenotypic  characterization  of the  anti-I-A 
antibody-induced Ts as a  Ts~, Ts2, or Ts3 cell, each of which has distinct receptors 
specificities and activation signals (43-46), should aid in elucidating the mechanism 
by which Ir gene function is blocked and Ts induction occurs under these conditions. 
The observation  that  antigen-specific suppressor T  cells are  induced by in  vivo 
treatment with I-A subregion-specific antibodies serves not only to clarify the biolog- 
ical  actions  of these proteins, but  also  provides a  means  for generating functional 
suppressor molecules against  the myriad of antigens that are dependent upon mac- 
rophage I-A-restricted presentation. The potential benefits of this approach to clinical 
manipulation of inappropriate T  cell responses has already been demonstrated by the 
capacity  of anti-I-A  antibody  treatment  to  prevent  the  development  of murine 
experimental  allergic encephalitis  (21).  Based  upon  our previous observation  that 
I-A-specific antibodies also inhibit host T cell responses to non-H-2 histocompatibility 
antigens  (24),  we  are  currently  focusing  on  anti-I-A  treatment  as  a  therapeutic 488  ANTI-I-A ANTIBODY-INDUCED SUPPRESSOR T  CELLS 
approach to manipulating transplant rejection in animals differing at minor histocom- 
patibility loci. The immunological specificity inherent in this means of treatment, as 
well as its demonstrated effectiveness in regulating cellular responses in a  variety of 
experimental situations,  suggests that  similar reagents may be readily applicable to 
the modulation of Ir gene function in human disease. 
Summary 
The  in  vivo  administration  of antibodies  specific  for  gene  products  of the  I-A 
subregion  represents an  immunologically specific approach to the  manipulation  of 
Ly-1  +  T  cell  responses  to  antigen.  This  has  been  demonstrated  previously by the 
capacity of anti-I-A antibody  treatment  to  abrogate T  cell-mediated delayed-type 
hypersensitivity (DTH) responses to syngeneic tumor antigen, hapten, and non-H-2 
histocompatibility  antigens.  Evidence  obtained  in  these  studies  suggested  that  the 
primary action of antibody was related to its ability to interfere with macrophage-T 
cell interactions during antigen presentation, consistent with the demonstration that 
similar  antibodies  inhibit  T  cell  binding  to  antigen-pulsed  macrophages  in  vitro. 
Results presented in this report provide evidence for an additional consequence of in 
vivo antibody administration  that  may be secondary to  any direct  effects on  I-A- 
restricted  antigen  presentation.  Thus,  animals  treated  with  I-A subregion-specific 
antibodies also develop a population of antigen-specific suppressor T  cells (Ts) capable 
of inhibiting  recipient  Ly-1 ÷ T  cell  responses  to  tumor antigen.  The  induction  of 
suppression appeared to be an essential component of the total biological activity of 
these  antibodies,  because  elimination  of Ts  precursors  by  cyclophosphamide  also 
abrogated the antibody-mediated inhibition of DTH responsiveness. These results are 
discussed  with  respect  to  the  possible  mechanisms  of  Ts  activation  by  anti-I-A 
antibody administration, and the general applicability of this approach as a means of 
clinical immunotherapy to limit inappropriate T  cell responses in human disease. 
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